You are here

Inhaled Antimicrobial Drug Candidate BIOC51 Receives FDA’s QIDP Status

Agent treats certain chronic pulmonary infections in patients with cystic fibrosis

Novoclem Therapeutics, Inc., has announced that its inhaled antimicrobial drug candidate BIOC51 has been designated a qualified infectious disease product (QIDP) by the FDA.

The QIDP designation, granted for treatment of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis, will make BIOC51 eligible to benefit from certain incentives for the development of new antibiotics provided under the Generating Antibiotic Incentives Now Act (GAIN Act). These incentives include priority review and eligibility for fast-track status. In addition, if ultimately approved by the FDA, BIOC51 is eligible for an additional five-year extension of market exclusivity.

“Chronic, persistent lung infections with Pseudomonas aeruginosa are a major factor impacting the poor quality of life and untimely death in cystic fibrosis patients,” Anne Whitaker, Chief Executive Officer of Novoclem Therapeutics, said in a press release. “The QIDP designation will accelerate the advancement of BIOC51 development as a potential treatment for these patients.”

BIOC51 is a novel polyglucosamine biopolymer covalently modified with N-diazeniumdiolate nitric oxide (NO) donors to facilitate spontaneous (without the need of enzymes) and controlled NO release. The level of NO release from BIOC51 has proven sufficient for eradicating planktonic and biofilm-based bacteria, and can be delivered to the lungs as a dry powder or solution (e.g., nebulization).

Cystic fibrosis (CF) is a rare life-threatening hereditary disease characterized by the production of thick, hard-to-clear mucus within the lung, leading to recurrent lung infections and loss of lung function. Antibiotic therapy, routinely used to treat lung infections in people with CF, becomes ineffective as bacterial resistance develops. The thick mucus within the lungs also makes it difficult for antibiotics to penetrate bacterial colonies, so there is a great need to develop alternative agents that can treat bacterial infection in people with CF.

Source: PR Newswire; November 7, 2017.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs